Study of the Carrier State for Five BRCA1/BRCA2 Deleterious Mutations in Bulgarian Women with Breast Cancer
By:
References
- 1. Bulgarian national cancer registry. Cancer incidence in Bulgaria - data for 2010. [cited 2013 Nov 2]. Available from: http://www.sbaloncology.bg/en/ncr.html
- 2. Broca P, Traite’ des tumeurs. Paris: P. Asselin; 1866.
- 3. Collaborative Group on Hormonal Factors idisease. Lancet 2001 ;358(9291 ):1389-99.
- 4. Thompson D, Easton D.The genetic epidemiology of breast cancer genes. J Mammary Gland Biol Neoplasia. 2 004;9(3 ):221-36.
- 5. American College of Obstetricians and Gynecologists; ACOG Committee on Practice Bulletins-Gynecology; ACOG Committee on Genetics; Society of Gynecologic Oncologists. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome. Obstet Gy necol 2009; 113(4):957-66.
- 6. National Cancer Institute [Internet]. Genetic testing for hereditary cancer syndromes, [updated 2013 Oct 4; cited 2013 Nov 2]. Available from: http://vvww.cancer.gov/cancertopics/fact.sheet/Risk/genetic-testing
- 7. Hughes KS, Ravnikar V. Risk assessment and management of women with BRCA mutations. A Supplement to The Female Patient. 2009, Nov.
- 8. National Cancer Center Network. Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and (Xarian. [cited 2013 Nov 2]. Available at: www.nccn.org/professionals/physician_gls/PDF7genetics_screening.pdf.
- 9. Wooster R, Weber BL. Breast and ovarian cancer. NEnglJ Med. 2003;48(23):2339-47.
- 10. Lakhani SR, Jacquemier J, Sloan JP, Gusterson BA, Anderson TJ, van de Vijver MJ, et al. Multi factorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Insl 1998;90( 15): 1138-45.
- 11. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004;4<9): 665-76.
- 12. Agnarsson BA, Jonasson JG, Bjomsdottir IB, Barkardottir RB, Egilsson V, Sigurdsson H. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat. 1998;4 7(2): 121 -7.
- 13. National Human Genome research Institute [Internet]. Breast cancer information core Breast cancer, [cited 2013 Nov 2]. Available from: http://research.nhgri.nih.gov/projectsbic/
- 14. Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91(11 ):943-9.
- 15. SerovaOM, MazoyerS, PugetN, DuboisV,Tonin P, Shugart YY, et al. Mutations in BRCA1 and BRCA2 in breast cancer families: are there more breast cancer-susceptibility genes? Am J Hum Genet. 1997;60(3):486-95.
- 16. LevenatS, Musani V, Cvok ML, Susac I, Sabo! M, Gzretic P, et al. Three novel BRCA1/BRCA2 mutations in breast/’ovarian cancer families in Croat ia.Gene. 2012;498(2):169-76.
- 17. Tucker JM, Rizk B. Hereditary female cancers: Breast, ovarian, and endometrial. Middle East Fertil Soc J. 2011;16(4):241-7.
- 18. National statistic institute [Internet]. Mortality by causes, sex and age. [cited 2013 Nov 2]. Available from: httpi/Zw'ww. nsi.bg’otrasal.php.'otr 22
- 19. Cancer Research UK [Internet]. Breast cancer. Breast cancer incidence statistics, [updated 2012 Nov 7; cited 2013 Nov 2].Available from: http://www1.cancerreserchuk.org/cancer-info/cancerstats/types/breast/incidenece/uk-breast-cancer-incidenece-statistics
- 20. Evans DGR, Fentiman IS, McPherson K, Asbury D, Ponder BAJ, Howell A Familial breast cancer. BMJ. 1994;308:183-7.
- 21. Reis-Filho JS,Tutt AN. Triple negative tumours: a critical review. Hlstopathology. 2008;52( 1): 108-18.
- 22. Haffty BG.,Yang Q, Reiss M, KearneyT, Higgins SA, Weidhaas J, et al. Locoregkmal relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin On col. 2006;24(3 6):5652 -7.
- 23. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer. 2007;109(l):25-32.
- 24. Dent R, Trudeau M, Pritchard Kl, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical feature sand pat ter ns of recurrence. Clin Cancer Res. 2007;!3(15 Pt 1): 4429-34.
- 25. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res. 2009; 11(3 ):R31.
- 26. Lels HP Jr. Managing the remaining breast Cancer. 1980;46( Suppl 4): 1026-30.
- 27. Adami HO, Bergstrom R, Hansen J. Age at first primary as a determinant of the incidence of bilateral breast cancer. Cancer. 1985;55(3):643-7.
- 28. Engin K. Prognostic factors in bilateral breast cancer. Neoplasma. 1994;41(6):353-7.
- 29. Rogozinska-Szczepka J, Utracka-Hutka B, Grzybowska E, Maka B, Nowicka E, Smok-Ragankiew'icz A, et al; BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. Ann Oncol. 2004; 15(9): 13 73-6.
- 30. Palma MD, DomchekSM, Stopfer J, Erlichman J, Siegfried JD, Tigges-Cardwell J, et al. The relative contribution of point mutations and genomic rearrange me nts in BRCA1 and BRCA2 in high-risk breast cancer families. Cancer res. 2008;68( 17):7006-14.
- 31. Gorski B, Narod S, Lubinski J. A common missense variant in BRCA2 predispose to early onset breast cancer. Breast Cancer Res. 2005;7(6):R 1023-7.
- 32. Sliwinski T, Krupa R, Majsterek I, Rykala J, Kolacinska A, Morawiec Z, et al. Polymorphisms of the BRCA2 and R AD51 genes in breast cancer. Breast Cancer Res Treat. 200<S:94t2V 105-9
DOI: https://doi.org/10.1515/jbcr-2015-0109 | Journal eISSN: 1313-9053
Language: English
Page range: 100 - 105
Submitted on: Jul 1, 2013
Accepted on: Dec 27, 2013
Published on: Nov 30, 2016
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 2 times per year
Keywords:
Related subjects:
© 2016 Katia S. Kovacheva, Zornica B. Kamburova, Savelina L. Popovska, Ivan N. Ivanov, Maria N. Simeonova, Petia N. Angelova, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.